Budget Impact Analysis of Erlotib as the First-Line Therapy of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1550
https://www.valueinhealthjournal.com/article/S1098-3015(16)01618-1/fulltext
Title :
Budget Impact Analysis of Erlotib as the First-Line Therapy of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01618-1&doi=10.1016/j.jval.2016.03.1550
First page :
A142
Section Title :
Cancer - Cost Studies
Open access? :
No
Section Order :
265